1. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
- Author
-
Chirwa LI, Johnson JA, Niska RW, Segolodi TM, Henderson FL, Rose CE, Li JF, Thigpen MC, Matlhaba O, Paxton LA, and Brooks JT
- Subjects
- Adenine analogs & derivatives, Adenine therapeutic use, Botswana epidemiology, CD4 Lymphocyte Count, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Emtricitabine, HIV isolation & purification, HIV Infections immunology, Heterosexuality, Humans, Organophosphonates therapeutic use, Plasma virology, Tenofovir, Anti-HIV Agents therapeutic use, Chemoprevention methods, Drug Resistance, Viral, HIV Infections drug therapy, HIV Infections virology, Post-Exposure Prophylaxis methods, Viral Load
- Abstract
We examined CD4 cell count and plasma viral load patterns among Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing participants assigned to receive tenofovir/emtricitabine with participants assigned to receive placebo. We also evaluated for antiretroviral drug resistance among the breakthrough HIV infections. Among nine seroconverters assigned to tenofovir/emtricitabine and 24 to placebo, there were no significant differences in their CD4 cell count or viral load profiles over time. Of the four participants who seroconverted on-study while receiving tenofovir/emtricitabine, none became infected as a result of drug-resistant HIV; moreover, no resistance mutations emerged following seroconversion.
- Published
- 2014
- Full Text
- View/download PDF